Compare FBDT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBDT | RNTX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 50.9M |
| IPO Year | 2026 | 2017 |
| Metric | FBDT | RNTX |
|---|---|---|
| Price | $0.85 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 212.2K | ★ 899.0K |
| Earning Date | 11-16-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.28 |
| 52 Week High | $1.25 | $2.10 |
| Indicator | FBDT | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 24.57 |
| Support Level | $0.73 | N/A |
| Resistance Level | $1.03 | $0.91 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 17.22 | 15.43 |
First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.